0
0

Chapter 21. Mirtazapine

Alan F. Schatzberg, M.D.
DOI: 10.1176/appi.books.9781585623860.413301

Sections

Excerpt

Mirtazapine, originally known as ORG 3770, was first synthesized by the Department of Medicinal Chemistry of NV Organon in the Netherlands (Kaspersen et al. 1989). First approved for use in major depression in the Netherlands in 1994, mirtazapine was introduced in the United States in 1996. The new drug application consisted of 47 Phase II/III clinical trials involving 2,796 mirtazapine-treated patients, 605 placebo-treated patients, and 1,161 active-control patients (Fawcett and Barkin 1998b).

Your session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

FIGURE 21–1. Chemical structure of mirtazapine.

References

American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC, American Psychiatric Association, 1994
 
Barkin RL, Schwer W, Barkin SJ: Recognition and management of depression in primary care: a focus on the elderly. A pharmacotherapeutic overview of the selection process among the traditional and new antidepressants. Am J Ther 7:205–226, 2000
[PubMed]
 
Bendtsen L, Jensen R: Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology 62:1706–1711, 2004
[PubMed]
 
Bengtsson HJ, Kele J, Johansson J, et al: Interaction of the antidepressant mirtazapine with 2 adrenoceptors modulating the release of 5-HT in different rat brain regions in vivo. Naunyn Schmiedebergs Arch Pharmacol 362:406–412, 2000
[PubMed]
 
Benkert O, Szegedi A, Kohnen R: Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 61:656–663, 2000
[PubMed]
 
Benkert O, Szegedi A, Philipp M, et al: Mirtazapine orally disintegrating tables versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder. J Clin Psychopharmacol 26:75–78, 2006
[PubMed]
 
Berendsen HHG, Broekkamp CLE: Indirect in vivo 5-HT1A-agonistic effects of the new antidepressant mirtazapine. Psychopharmacology (Berl) 133:275–282, 1997
[PubMed]
 
Berk M, Ichim C, Brook S: Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int Clin Psychopharmacol 16:87–92, 2001
[PubMed]
 
Boyarsky BK, Haque W, Rouleau MR, et al: Sexual functioning in depressed outpatients taking mirtazapine. Depress Anxiety 9:175–179, 1999
[PubMed]
 
Brannon GE, Stone KD: The use of mirtazapine in a patient with chronic pain. J Pain Symptom Manage 18:382–385, 1999
[PubMed]
 
Brannon GE, Rolland PD, Gary JM: Use of mirtazapine as prophylactic treatment for migraine headache. Psychosomatics 41:153–154, 2000
[PubMed]
 
Carley DW, Olopade C, Ruigt GS, et al: Efficacy of mirtazapine in obstructive sleep apnea syndrome. Sleep 30:35–41, 2007
[PubMed]
 
Carpenter LL, Yasmin S, Price L: A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 51:183–188, 2002
[PubMed]
 
Chung MY, Min KH, Jun YJ, et al: Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Hum Psychopharmacol 19:489–494, 2004
[PubMed]
 
Claghorn JL, Lesem MD: A double-blind placebo-controlled study of Org 3770 in depressed outpatients. J Affect Disord 34:165–171, 1995
[PubMed]
 
Connor KM, Davidson JRT, Weisler RH, et al: A pilot study of mirtazapine in post-traumatic stress disorder. Int Clin Psychopharmacol 14:29–31, 1999
[PubMed]
 
Dahl ML, Voortman G, Alm C, et al: In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin Drug Invest 13:37–46, 1997
 
De Boer T: The pharmacologic profile of mirtazapine. J Clin Psychiatry 57 (suppl 4):19–25, 1996
 
De Boer T, Ruigt GCF, Berendsen HHG: The -2 adrenoceptor antagonist Org 3770 (mirtazapine, Remeron®) enhances noradrenergic and serotonergic transmission. Hum Psychopharmacol Clin Exp 10 (suppl):S107–S118, 1995
 
Djulus J, Koren G, Einarson TR, et al: Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry 67:1280–1284, 2006
[PubMed]
 
Dodd S, Burrows GD, Norman TR: Chiral determination of mirtazapine in human blood plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 748:439–443, 2000
[PubMed]
 
Dunner DL, Hendrickson HE, Bea C, et al: Dysthymic disorder: treatment with mirtazapine. Depress Anxiety 10:68–72, 1999
[PubMed]
 
Farah A: Lack of sexual adverse effects with mirtazapine. Am Health Syst Pharm 55:2195–2196, 1998
[PubMed]
 
Fava M, Dunner DL, Greist JH, et al: Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry 62:413–420, 2001
[PubMed]
 
Fava M, Rush AJ, Wisniewski SR, et al: A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 163:1161–1172, 2006
[PubMed]
 
Fawcett J, Barkin RL: A meta-analysis of eight randomized, double-blind controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry 59:123–127, 1998a
 
Fawcett J, Barkin RL: Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 51:267–285, 1998b
 
Freynhagen R, Muth-Selbach U, Lipfert P, et al: The effect of mirtazapine in patients with chronic pain and concomitant depression. Curr Med Res Opin 22:257–264, 2006
[PubMed]
 
Gambi F, De Berardis D, Campanello D, et al: Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study. J Psychopharmacol 19:483–487, 2005
[PubMed]
 
Gelenberg AJ, Laukes C, McGauhey C, et al: Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry 61:356–360, 2000
[PubMed]
 
Goodnick PJ, Puig A, DeVane CL, et al: Mirtazapine in major depression with comorbid generalized anxiety disorder. J Clin Psychiatry 60:446–448, 1999
[PubMed]
 
Guelfi JD, Ansseau M, Timmerman L, et al: Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 21:425–431, 2001
[PubMed]
 
Haapasalo-Pesu KM, Vuola T, Lahelma L, et al: Mirtazapine in the treatment of adolescents with major depression: an open-label, multicenter pilot study. J Child Adolesc Psychopharmacol 14:175–184, 2004
[PubMed]
 
Halikas JA: Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Hum Psychopharmacol 10:125–133, 1995
 
Holm KJ, Markham A: Mirtazapine: a review of its use in major depression. Drugs 57:607–631, 1999
[PubMed]
 
Holzbach R, Jahn H, Pajonk FG, et al: Suicide attempts with mirtazapine overdose without complications. Biol Psychiatry 44:925–926, 1998
[PubMed]
 
Joffe H, Groninger H, Soares C, et al: An open trial of mirtazapine in menopausal women with depression unresponsive to estrogen replacement therapy. J Womens Health Gend Based Med 10:999–1004, 2001
[PubMed]
 
Kaspersen FM, van Rooij FAM, Sperling EMG: The synthesis of Org 3770 labeled with 3-H, 13-C and 14-C. J Labelled Comp Radiopharma 27:1055–1068, 1989
 
Kast RE: Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. Support Care Cancer 9:469–470, 2001
[PubMed]
 
Kent JM: SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 355:911–918, 2000
[PubMed]
 
Kim W, Pae CU, Chae JH, et al: The effectiveness of mirtazapine in the treatment of post-traumatic stress disorder: a 24-week continuation therapy. Psychiatry Clin Neurosci 59:743–747, 2005
[PubMed]
 
Kooyman AR, Zwart R, Vanderheijden PM, et al: Interaction between enantiomers of mianserin and Org 3770 at 5-HT3 receptors in cultured mouse neuroblastoma cells. Neuropsychopharmacology 33:501–510, 1994
[PubMed]
 
Koran LM, Gamel NN, Choung HW, et al: Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry 66:515–520, 2005
[PubMed]
 
Kristensen JH, Ilett KF, Rampono J, et al: Transfer of the antidepressant mirtazapine into breast milk. Br J Clin Pharmacol 63:322–327, 2007
[PubMed]
 
Kuiken TA, Schechtman L, Harden RN: Phantom limb pain treatment with mirtazapine: a case series. Pain Pract 5:356–360, 2005
[PubMed]
 
Laakmann G, Hennig J, Baghai T, et al: Mirtazapine acutely inhibits salivary cortisol concentrations in depressed patients. Ann N Y Acad Sci 1032:279–282, 2004
[PubMed]
 
Leinonen E, Skarstein J, Behnke K, et al: Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Int Clin Psychopharmacol 14:329–337, 1999
[PubMed]
 
Maris FA, Dingler E, Niehues S: High-performance liquid chromatographic assay with fluorescence detection for the routine monitoring of the antidepressant mirtazapine and its desmethyl metabolite in human plasma. J Chromatogr B Biomed Sci Appl 721:309–316, 1999
[PubMed]
 
Michelson D, Kociban K, Tamura R, et al: Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial. J Psychiatr Res 36:147–152, 2002
[PubMed]
 
Montgomery SA: Safety of mirtazapine: a review. Int Clin Psychopharmacol 10 (suppl 4):37–45, 1995
 
Mrakotsky C, Masek B, Biederman J, et al: Prospective open-label pilot trial of mirtazapine in children and adolescents with social phobia. J Anxiety Disord 22:88–97, 2008
[PubMed]
 
Muehlbacher M, Nickel MK, Nickel C, et al: Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 25:580–582, 2005
[PubMed]
 
Murphy GM, Kremer C, Rodrigues H, et al: The apolipoprotein E epsilon4 allele and antidepressant efficacy in cognitively intact elderly depressed patients. Biol Psychiatry 54:665–673, 2003
[PubMed]
 
Nelson JC, Holden K, Roose S, et al: Are there predictors of outcome in depressed elderly nursing home residents during treatment with mirtazapine orally disintegrating tablets? Int J Geriatr Psychiatry 22:999–1003, 2007
[PubMed]
 
Numazawa R, Yoshioka M, Matsumoto M, et al: Pharmacological characterization of -2 adrenoceptor regulated serotonin release in the rat hippocampus. Neurosci Lett 192:161–164, 1995
[PubMed]
 
Nutt DJ: Efficacy of mirtazapine in clinically relevant subgroups of depressed patients. Depress Anxiety 7 (suppl 1):7–10, 1998
 
Nutt D: Treatment of cluster headache with mirtazapine. Headache 39:586–587, 1999
[PubMed]
 
Pallanti S, Quercioli L, Bruscoli M: Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry 65:1394–1399, 2004
[PubMed]
 
Posey DJ, Guenin KD, Kohn AE, et al: A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adolesc Psychopharmacol 11:267–277, 2001
[PubMed]
 
Poyurovsky M, Epshtein S, Fuchs C, et al: Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study. J Clin Psychopharmacol 23:305–308, 2003
[PubMed]
 
Poyurovsky M, Pashinian A, Weizman R, et al: Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial. Biol Psychiatry 59:1071–1077, 2006
[PubMed]
 
Raji MA, Brady SR: Mirtazapine for treatment of depression and comorbidities in Alzheimer's disease. Ann Pharmacother 35:1024–1027, 2001
[PubMed]
 
Remeron (package insert). Physicians' Desk Reference, 56th Edition. Montvale, NJ, Medical Economics Company, 2002
 
Saks BR: Mirtazapine: treatment of depression, anxiety, and hyperemesis gravidarum in the pregnant patient: a report of 7 cases. Arch Women Ment Health 3:165–170, 2001
 
Schatzberg AF, Kremer C, Rodrigues HE, et al: Double-blind randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 10:541–550, 2002
[PubMed]
 
Schmid DA, Wichniak A, Uhr M, et al: Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology 31:832–844, 2006
[PubMed]
 
Stahl S, Zivkov M, Reimitz PE, et al: Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Acta Psychiatr Scand Suppl 391:22–30, 1997
[PubMed]
 
Stimmel GL, Dopheide JA, Stahl SM: Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 17:10–21, 1997
[PubMed]
 
Theobold DE: A patient with B-cell lymphoma and major depression treated with mirtazapine. Primary Care and Cancer 20:61–63, 2000
 
Theobold DE, Kirsh KE, Holtszclaw E, et al: An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 23:442–447, 2002
 
Thompson DS: Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology. Psychosomatics 41:356–359, 2000
[PubMed]
 
Varia I, Venkataraman S, Hellegers C, et al: Effect of mirtazapine orally disintegrating tablets on health-related quality of life in elderly depressed patients with comorbid medical disorders: a pilot study. Psychopharmacol Bull 40:47–56, 2007
[PubMed]
 
Waldinger MD, Berendsen HHG, Schweitzer DH: Treatment of hot flushes with mirtazapine: four case reports. Maturitas 36:165–168, 2000
[PubMed]
 
Waring WS, Good AM, Bateman DN: Lack of significant toxicity after mirtazapine overdose: a five-year review of cases admitted to a regional toxicology unit. Clin Toxicol (Phila) 45:45–50, 2007
[PubMed]
 
Wheatley DP, Van Moffaert M, Timmerman L, et al: Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J Clin Psychiatry 59:306–312, 1998
[PubMed]
 
+

CME Activity

Add a subscription to complete this activity and earn CME credit.
Sample questions:
1.
Mirtazapine may be described as a
2.
Mirtazapine has high affinity for which of the following?
3.
Which of the following statements concerning mirtazapine’s pharmacokinetics is false?
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Content
Articles
Books
Helping Parents, Youth, and Teachers Understand Medications for Behavioral and Emotional Problems: A Resource Book of Medication Information Handouts, 3rd Edition > Chapter 40.  >
What Your Patients Need to Know About Psychiatric Medications, 2nd Edition > Chapter 27.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 23.  >
Topic Collections
Psychiatric News
PubMed Articles
 
  • Print
  • PDF
  • E-mail
  • Chapter Alerts
  • Get Citation